TMAO, produced in the gut when red meat and high-fat dairy are broken down, identified patients with rapidly growing AAAs.

These randomized results are encouraging, although the field awaits longer-term data to see how the leads hold up.

Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion focuses on the impact of transcatheter devices on HF patients and current ...

With so many options available for addressing the disease, it shouldn’t be accepted as inevitable, a scientific statement ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

New US hypertension guidelines, the first since 2017, released today reinforce prior recommendations that prioritize lowering ...

Yet 44% of the high-risk patients, from LAAO’s early era, died by 5 years—researchers say this knowledge can aid ...

Japanese registry data point to fewer deaths and heart failure hospitalizations, especially when MR is reduced to mild or ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

The advantage over balloon angioplasty in this higher-risk subset was consistent with the results seen in single-layer ISR.

Effects are more modest in placebo-controlled versus nonrandomized studies, with experts calling for further research.

The findings are encouraging but likely don’t apply to countries with ready access to thrombectomy, one expert says.